Skip to main content
Premium Trial:

Request an Annual Quote

FDA Proposes Reclassification of HCV RNA, Antibody Tests

NEW YORK – The US Food and Drug Administration on Wednesday proposed the reclassification of two types of hepatitis C virus (HCV) diagnostic tests from class III to class II, meaning the devices will go through the agency's 510(k) pathway for clearance instead of the more rigorous premarket approval (PMA) pathway if the proposal is finalized.

The two types of tests are nucleic acid-based HCV ribonucleic acid (RNA) devices intended for the detection or genotyping of HCV RNA and certain HCV antibody devices intended for the detection of antibodies to HCV.

The reclassification, if finalized, would "reduce the regulatory burdens associated with these devices," the FDA said in a document. However, class II devices are required to comply with special controls to provide a reasonable assurance of safety and effectiveness.

The agency said it is also proposing that the reclassification uses the names hepatitis C virus (HCV) antibody tests and nucleic acid-based hepatitis C virus (HCV) ribonucleic acid tests. In the current classification, they are named hepatitis C virus antibody assay devices and nucleic acid-based hepatitis C virus ribonucleic acid assay devices.


The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.